A Comparative Evaluation of Anti-Inflammatory and Arthritic Effects of bradykinin inhibitor Zaltoprofen over Piroxicam in Murine models: A randomized experimental study.

Background and Aims: Inflammation is an essential biochemical protective response of vascularized tissues, broadly classified into acute and chronic inflammation. Zaltoprofen, a unique propionic acid group of NSAID, acts by blocking the augmenting effect of bradykinin. The present study was conducted to evaluate the acute and chronic anti-inflammatory (arthritic) potential of Zaltoprofen over piroxicam in murine models. Methods:A total of 24 healthy Wister rats (200–250 g) of either sex (24 in each model) were obtained from the central animal house, AIIMS, Bhopal and categorized into four different groups, six in each. Zaltoprofen was used as a test and Piroxicam as a Standard (Per Os) agent. The anti-inflammatory or arthritic potential was evaluated and compared by acute and chronic inflammation (carrageenan and formalin-induced)models. Results:In the acute inflammation model, Zaltoprofen when compared to Negative control (NaCl 10ml/kg) there was a significant inhibition in paw volume (P< 0.001) at different time scales with two different doses of Test compound (Zaltoprofen 10&20mg/kg). However, in the chronic inflammation model, Zaltoprofen 10 mg/kg & 20mg/kg doses of the Test compound had been shown a significant reduction in the chronic inflammation comparable to the negative control (NaCl 10ml/kg), though the efficacy was lesser than Positive control (Piroxicam 10mg/kg) (P≤ 0.05). Conclusions:Zaltoprofen possesses significant acute and chronic anti-inflammatory and arthritic effects by inhibiting various inflammatory mediators. Therefore, Zaltoprofen can be explored as a potential alternative agent for the treatment of acute inflammatory and chronic inflammatory or arthritis conditions in human beings.